On September 28th, the VNVC Vaccination Center System held a strategic cooperation signing ceremony with Takeda Pharmaceuticals (Asia Pacific) Co., Ltd., a subsidiary of Takeda Group of Japan.
The collaboration between Vietnam's leading vaccination center system and Takeda, a world- leading pharmaceutical company, is expected to soon provide opportunities for Vietnamese people to access and apply dengue fever prevention solutions, especially dengue fever vaccines.
At the signing ceremony, both sides agreed to implement many important activities, affirming a sustainable development strategy with the goal of training, scientific research, etc., to promote awareness and improve professional knowledge for medical staff on dengue fever prevention measures, including dengue fever vaccines.
Attending the signing ceremony, Dr. Nguyen Ngo Quang, Deputy Director of the Department of Science, Technology and Training ( Ministry of Health ), highly appreciated the cooperation between Takeda and VNVC - Vietnam's leading complete vaccination system. Dr. Quang expressed his hope that the cooperation between Takeda and VNVC will bring practical benefits to the people in the near future.
"We hope that the people of Vietnam will have access to the dengue fever vaccine as soon as possible," Mr. Quang said.
Having worked for many years in the field of preventive medicine and vaccination, Associate Professor Dr. Tran Dac Phu, former Director of the Department of Preventive Medicine and Senior Advisor to the Vietnam Center for Emergency Response to Public Health Events, shared that he has witnessed many outbreaks and deaths caused by dengue fever and understands better than anyone the role of vaccines in preventing many infectious diseases.
He highly appreciated VNVC's superior vaccination model and expressed his delight at VNVC's growth, reputation, and quality, with over 130 vaccination centers nationwide, making it easier for people to access new vaccines circulating worldwide.
He hopes that Vietnam will soon have a dengue fever vaccine, which will help reduce the number of cases and deaths caused by the disease, contributing to the sustainable eradication of this epidemic in Vietnam.
Representatives from Takeda Vietnam and VNVC Vaccination System signed a memorandum of understanding for strategic cooperation on September 28th in Ho Chi Minh City. Photo: Thanh Tung
At the signing ceremony, Mr. Ngo Chi Dung, Chairman of the Board of Directors and General Director of VNVC Vaccination Center System, shared that with its comprehensive capabilities, experience in vaccine preservation, and strategic partnership with many major vaccine manufacturers worldwide, VNVC is always interested in seeking and ready to cooperate with manufacturers to promptly bring new generation vaccines for diseases such as dengue fever, shingles, hand, foot and mouth disease, and hepatitis B to serve the Vietnamese people.
"VNVC has fully prepared the best conditions to cooperate with Takeda Group in raising awareness about dengue fever. This collaboration opens up prospects for applying advanced measures to prevent dengue fever, especially through dengue fever vaccines, in the future in Vietnam," Mr. Dung said expectantly.
Speaking at the signing ceremony, Ms. Katharina Geppert, Head Representative of Takeda Vietnam, shared: "We are delighted to cooperate with VNVC to bring Takeda's high-quality preventive and healthcare solutions closer to the people of Vietnam. At Takeda, we highly value the strength of cooperation between healthcare partners in each country to jointly address public health challenges, including solutions in dengue fever prevention and control."
Following the signing ceremony, Takeda also collaborated with the Pasteur Institute of Ho Chi Minh City to organize a workshop titled "Orientations and Solutions to Improve the Effectiveness of Dengue Fever Prevention and Control in Vietnam." This was an important event within the series of activities held to commemorate the 50th anniversary of diplomatic relations between Vietnam and Japan.
Children receive vaccinations at the VNVC Vaccination System.
It is known that Takeda's dengue fever vaccine, TAK-003 (registered trade name QDENGA), has been licensed for use in more than 30 countries, including the European Union (EU), the United Kingdom, Argentina, and countries with dengue fever epidemiological situations similar to Vietnam, such as Indonesia, Brazil, and more recently, Thailand. TAK-003 currently does not have a marketing authorization in Vietnam.
Test results show that the vaccine can generate varying levels of immunity against all four circulating strains of the Dengue virus, helping to prevent the disease and reduce the likelihood of hospitalization for people with dengue fever.
According to the European Medicines Agency (EMA), the body that licenses vaccines in the EU, the QDENGA vaccine has been approved for use in children aged 4 years and older, regardless of whether they have previously been infected.
With over 130 centers nationwide, VNVC is the leading vaccination center system for children and adults in Vietnam. VNVC has a system of 4 main cold storage facilities and more than 130 cold storage warehouses meeting international GSP standards and a cold chain system at all vaccination centers nationwide, capable of storing up to 300 million vaccine doses simultaneously.
Besides Takeda, VNVC is also a comprehensive strategic partner with many major vaccine manufacturers worldwide such as GSK (Belgium), Sanofi (France), AstraZeneca (UK), Pfizer (USA), MSD (USA), etc.
Source link
Comment (0)